NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free CYCC Stock Alerts $1.75 -0.03 (-1.69%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.73▼$1.9350-Day Range$1.58▼$2.9752-Week Range$1.52▼$13.20Volume24,427 shsAverage Volume130,548 shsMarket Capitalization$2.31 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media Get Cyclacel Pharmaceuticals alerts: Email Address Cyclacel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,100.0% Upside$21.00 Price TargetShort InterestHealthy2.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($18.70) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 stars 3.3 Analyst's Opinion Consensus RatingCyclacel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCyclacel Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.03% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently decreased by 8.65%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYCC. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.47% of the stock of Cyclacel Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cyclacel Pharmaceuticals are expected to grow in the coming year, from ($18.70) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Read More CYCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCC Stock News HeadlinesApril 20, 2024 | americanbankingnews.comAnalyzing Lexicon Pharmaceuticals (NASDAQ:LXRX) & Cyclacel Pharmaceuticals (NASDAQ:CYCC)April 16, 2024 | americanbankingnews.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.comApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 1, 2024 | globenewswire.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerMarch 27, 2024 | money.usnews.comCyclacel Pharmaceuticals IncMarch 21, 2024 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | msn.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 19, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditFebruary 22, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (CYCCP)February 20, 2024 | globenewswire.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 15, 2024 | finance.yahoo.comCyclacel Pharmaceuticals Inc. (UXI.SG)January 8, 2024 | finance.yahoo.comCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequirementDecember 22, 2023 | msn.comWhy Cyclacel Pharmaceuticals (CYCC) Shares Are Getting ObliteratedDecember 22, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq RulesDecember 20, 2023 | msn.comBrookline Capital Downgrades Cyclacel Pharmaceuticals (CYCC)December 15, 2023 | benzinga.comCyclacel Pharmaceuticals Stock (NASDAQ:CYCC) Dividends: History, Yield and DatesDecember 12, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Reverse Stock SplitNovember 30, 2023 | msn.comCyclacel Pharmaceuticals regains compliance with Nasdaq listing rulesNovember 28, 2023 | benzinga.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 28, 2023 | finance.yahoo.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 27, 2023 | msn.comCyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94November 24, 2023 | morningstar.comCyclacel Pharmaceuticals Inc CYCCSee More Headlines Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CYCC CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees2,018Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+1,100.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($27.2195) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,560,000.00 Net MarginsN/A Pretax Margin-6,083.57% Return on Equity-448.19% Return on Assets-151.29% Debt Debt-to-Equity RatioN/A Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$420,000.00 Price / Sales5.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book3.07Miscellaneous Outstanding Shares1,320,000Free Float1,206,000Market Cap$2.31 million OptionableOptionable Beta0.54 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 65)President, CEO & Executive Director Comp: $612.47kMr. Paul McBarron (Age 63)Executive VP of Finance, CFO, COO, Secretary & Executive Director Comp: $321.61kMs. Gill Christie (Age 67)Director of Human Resources Dr. Brian Schwartz M.D. (Age 61)Interim Chief Medical Officer & Director Comp: $51kGrace KimInvestor Relations ExecutiveKey CompetitorsCNS PharmaceuticalsNASDAQ:CNSPNotable LabsNASDAQ:NTBLSalarius PharmaceuticalsNASDAQ:SLRXHistogenNASDAQ:HSTOCohBarNASDAQ:CWBRView All CompetitorsInsidersSpiro George RombotisBought 6,070 shares on 12/21/2023Total: $20,091.70 ($3.31/share)Paul McbarronBought 1,886 shares on 12/21/2023Total: $6,242.66 ($3.31/share)View All Insider Transactions CYCC Stock Analysis - Frequently Asked Questions Should I buy or sell Cyclacel Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYCC shares. View CYCC analyst ratings or view top-rated stocks. What is Cyclacel Pharmaceuticals' stock price target for 2024? 2 brokerages have issued 12-month price objectives for Cyclacel Pharmaceuticals' stock. Their CYCC share price targets range from $21.00 to $21.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 1,100.0% from the stock's current price. View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts. How have CYCC shares performed in 2024? Cyclacel Pharmaceuticals' stock was trading at $2.67 on January 1st, 2024. Since then, CYCC stock has decreased by 34.5% and is now trading at $1.75. View the best growth stocks for 2024 here. Are investors shorting Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 24,300 shares, a drop of 8.6% from the March 15th total of 26,600 shares. Based on an average daily trading volume, of 145,700 shares, the short-interest ratio is currently 0.2 days. Currently, 2.0% of the shares of the company are short sold. View Cyclacel Pharmaceuticals' Short Interest. When is Cyclacel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CYCC earnings forecast. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its earnings results on Tuesday, March, 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts' consensus estimates of ($6.35) by $0.12. The biotechnology company earned $0.03 million during the quarter. When did Cyclacel Pharmaceuticals' stock split? Shares of Cyclacel Pharmaceuticals reverse split on Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO? 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA). How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYCC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
